Influence of Intravitreal Therapy on Choroidal Thickness in Patients with Diabetic Macular Edema

被引:2
|
作者
Mirete, Patricia [1 ,2 ,3 ]
Munoz-Morata, Carmen [3 ]
Albarran-Diego, Cesar [3 ]
Espana-Gregori, Enrique [1 ,3 ]
机构
[1] Hosp Univ & Politecn La Fe, Dept Ophthalmol, Valencia 46026, Spain
[2] Aiken Clin, Valencia 46004, Spain
[3] Univ Valencia, Dept Surg, Valencia 46010, Spain
关键词
anti-VEGF; diabetic macular edema; dexamethasone implant; intravitreal therapy; OCT; aflibercept; ranibizumab; choroid; OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF; RETINOPATHY; BIOMARKERS; MANAGEMENT;
D O I
10.3390/jcm12010348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to analyze the variation in subfoveal choroidal thickness (SFCT) and its relationship with the variation in central macular thickness (CME) in response to intravitreal therapy with an antiangiogenic (anti-VEGF) drug or corticosteroid in type 2 diabetic patients with diabetic macular edema (DME). Material and methods: This retrospective study included 70 eyes of 35 patients: 26 eyes received 4-5 intravitreal injections of aflibercept, 26 eyes were treated with a single intravitreal implant injection of dexamethasone, and 18 eyes without DME did not receive intravitreal therapy. SPECTRALIS (R) optical coherence tomography (OCT) (Heidelberg Engineering, Heidelberg, Germany) was used to measure the SFCT and CME before and at the end of the follow-up period. Results: The mean reductions in CME were 18.8 +/- 14.7% (aflibercept) and 29.7 +/- 16.9% (dexamethasone). The mean reductions in SFCT were 13.8 +/- 13.1% (aflibercept) and 19.5 +/- 9.6% (dexamethasone). The lowering effects of both parameters were significantly greater in the group treated with the dexamethasone implant (p = 0.022 and p = 0.046 for CMT and SFCT, respectively). Both therapies significantly decreased both CME and SFCT, independent of factors such as age, sex, previous intravitreal therapy, antidiabetic treatment, and the time of diabetes progression. There were no changes in the mean values of CME and SFCT in the untreated eyes. Conclusions: SFCT significantly decreased in response to intravitreal therapy with anti-VEGF or corticosteroids, irrespective of age, sex, previous intravitreal therapy, antidiabetic treatment, and the time of diabetes progression. There was a correlation between the changes in CME and SFCT after intravitreal therapy with aflibercept or dexamethasone implantation. SFCT was not a good predictor of the CME response but could be used to monitor the response to treatment. Local intravitreal therapy only affected the treated eye.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [41] CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY
    Nourinia, Ramin
    Ahmadieh, Hamid
    Nekoei, Elnaz
    Malekifar, Parviz
    Tofighi, Zahra
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (05): : 970 - 975
  • [42] Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema
    Chung, Eun Jee
    Roh, Mi In
    Kwon, Oh Woong
    Koh, Hyoung Jun
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (07): : 957 - 963
  • [43] Changes in Choroidal Thickness in Relation to the Severity of Retinopathy and Macular Edema in Type 2 Diabetic Patients
    Kim, Jee Taek
    Lee, Dong Hoon
    Joe, Soo Geun
    Kim, June-Gone
    Yoon, Young Hee
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (05) : 3378 - 3384
  • [44] Intravitreal Aflibercept for Diabetic Macular Edema
    Korobelnik, Jean-Francois
    Do, Diana V.
    Schmidt-Erfurth, Ursula
    Boyer, David S.
    Holz, Frank G.
    Heier, Jeffrey S.
    Midena, Edoardo
    Kaiser, Peter K.
    Terasaki, Hiroko
    Marcus, Dennis M.
    Nguyen, Quan D.
    Jaffe, Glenn J.
    Slakter, Jason S.
    Simader, Christian
    Soo, Yuhwen
    Schmelter, Thomas
    Yancopoulos, George D.
    Stahl, Neil
    Vitti, Robert
    Berliner, Alyson J.
    Zeitz, Oliver
    Metzig, Carola
    Brown, David M.
    OPHTHALMOLOGY, 2014, 121 (11) : 2247 - 2254
  • [45] Intravitreal Triamcinolone for Diabetic Macular Edema
    Giuliari, GianPaolo
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (24): : 2351 - 2351
  • [46] Choroidal Thickness After Dexamethasone Implant or Aflibercept in Patients with Diabetic Macular Edema Persistent to Ranibizumab
    Aksoy, Mustafa
    Yilmaz, Gursel
    Vardarli, Irfan
    Akkoyun, Imren
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 36 (08) : 629 - 635
  • [47] Intravitreal triamcinolone in diabetic macular edema
    Aslam, Sher
    Malik, Nabeel
    Davies, Nigel
    ARCHIVES OF OPHTHALMOLOGY, 2006, 124 (10) : 1506 - 1507
  • [48] Repeatability of Macular Thickness Measurements in Patients With Diabetic Macular Edema
    Invernizzi, A.
    Pellegrini, M.
    Cigada, M.
    Peroglio, A.
    Bassani, N.
    Staurenghi, G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [49] Progression and response predictive factors of diabetic macular edema in patients treated with intravitreal therapy
    Gutierrez, Angel
    Isabel Lopez, Maria
    Valentin Bravo, Francisco Javier
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [50] The impact of covid-19 on delivering intravitreal therapy to patients with diabetic macular edema
    Castro, Catarina
    Coelho, Joao
    Correia, Nuno
    Meneres, Pedro
    Pessoa, Bernardete
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)